The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.
February 5th 2021
February 5, 2021 - Durvalumab failed to improve overall survival over the EXTREME chemotherapy regimen in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with tumors expressed high levels of PD-L1, missing a primary end point of the phase 3 KESTREL trial.
January 21st 2021
Nabil F. Saba, MD, FACP, discusses the results of the JAVELIN Head and Neck 100 trial, as well as data from other key, recent studies in head and neck cancer.
January 18th 2021
Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.
January 8th 2021
January 8th, 2021 - The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab for use in patients with recurrent or metastatic head and neck squamous cell carcinoma who experienced disease progression during or after platinum-based chemotherapy.
December 31st 2020
In our exclusive interview, Robert Lindau, III, MD, discusses his journey into the head and neck surgery space, tips for a successful fellowship, and the importance of creating a family-like environment within the fellowship program he directs.